Viking Therapeutics (VKTX) Projected to Post Earnings on Wednesday

Key Points

• Viking Therapeutics is set to release its Q3 2025 earnings report on Wednesday, October 22nd, with analysts forecasting a loss of ($0.71) per share.
• The company's stock has recently experienced a 2.5% decline in trading, opening at $33.05, while analysts hold mixed ratings and price targets ranging from $31.00 to $125.00.
• Viking Therapeutics is focused on developing new therapies for metabolic disorders, with its lead drug candidate VK2809 currently in Phase IIb clinical trials.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) is projected to release its Q3 2025 results before the market opens on Wednesday, October 22nd. Analysts expect Viking Therapeutics to post earnings of ($0.71) per share for the quarter. Interested persons can check the company's upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, October 22, 2025 at 4:30 PM ET.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The biotechnology company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.14). The business's revenue for the quarter was up NaN% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.20) EPS. On average, analysts expect Viking Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Viking Therapeutics Trading Down 2.5%

Viking Therapeutics stock opened at $33.05 on Wednesday. The stock has a market cap of $3.72 billion, a P/E ratio of -21.60 and a beta of 0.64. The company has a fifty day simple moving average of $29.27 and a 200-day simple moving average of $28.18. Viking Therapeutics has a 12-month low of $18.92 and a 12-month high of $81.73.

Analysts Set New Price Targets

VKTX has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Viking Therapeutics in a report on Wednesday, October 8th. Citigroup upped their price target on Viking Therapeutics from $31.00 to $38.00 and gave the company a "neutral" rating in a report on Thursday, July 24th. HC Wainwright reaffirmed a "buy" rating and issued a $102.00 price target on shares of Viking Therapeutics in a report on Monday, September 29th. Raymond James Financial reduced their price objective on shares of Viking Therapeutics from $125.00 to $122.00 and set a "strong-buy" rating for the company in a research report on Thursday, July 24th. Finally, BTIG Research reiterated a "buy" rating and set a $125.00 price target on shares of Viking Therapeutics in a research note on Monday, September 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $86.42.

Hedge Funds Weigh In On Viking Therapeutics

Institutional investors have recently modified their holdings of the business. Royal Bank of Canada grew its position in Viking Therapeutics by 13.0% during the 1st quarter. Royal Bank of Canada now owns 347,716 shares of the biotechnology company's stock worth $8,396,000 after purchasing an additional 39,886 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new stake in shares of Viking Therapeutics during the first quarter worth about $230,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Viking Therapeutics by 1.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 470,028 shares of the biotechnology company's stock worth $11,351,000 after buying an additional 6,696 shares during the period. Prudential Financial Inc. purchased a new stake in Viking Therapeutics during the 2nd quarter valued at approximately $196,000. Finally, Northwestern Mutual Wealth Management Co. raised its stake in Viking Therapeutics by 29.5% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 2,109 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 481 shares during the last quarter. 76.03% of the stock is owned by institutional investors and hedge funds.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.